Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis

NCT00251719 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00251719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00251719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2005
Completion date
January 31, 2007
Enrollment
2,054 (actual)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

esophagitis, peptic, esophagitis, reflux